Pfizer Urges FDA To Prohibit Generic Exclusivity Transfer For Gabapentin
Executive Summary
Allowing generic drug companies to use "first-to-file" exclusivity as a licensable asset will lead to "speculative" ANDA filings, Pfizer warned in a citizen petition seeking to block approval of Teva's generic version of gabapentin (Neurontin)
You may also be interested in...
Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid
Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Teva and Ivax are moving into position to consider "at risk" launches of generic gabapentin (Pfizer's Neurontin)